UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): ~~May~~October 147, 2025

Nuo Therapeutics, Inc.

(Exact name of Registrant as Specified in Charter)

Delaware	000-28443	23-3011702
(State or Other Jurisdiction	(Commission	(IRS Employer
of Incorporation)	File Number)	Identification No.)

8285 El Rio, Suite 190, Houston, Texas 77054

(Address of Principal Executive Offices) (Zip Code)

(346) 396-4770

(Registrant’s telephone number, including area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act: None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934. Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

~~Emerging~~Item ~~growth~~5.02 ~~company~~Departure of Directors or Certain Officers; Election of Directors; ☐Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

IfOn anOctober ~~emerging~~7, ~~growth~~2025, ~~company~~the Board of Directors of Nuo Therapeutics, ~~indicate~~Inc. by(the ~~check~~“Company”) ~~mark~~and ifits Compensation, Nominating and Governance Committee (the ~~registrant~~“Committee”) ~~has~~approved ~~elected~~an ~~not~~increase toin ~~use~~the salaries of David E. Jorden, Chief Executive and Financial Officer of the ~~extended~~Company, ~~transition~~and ~~period~~Peter ~~for~~A. ~~complying~~Clausen, ~~with~~Chief ~~any~~Scientific ~~new~~and orOperating ~~revised~~Officer ~~financial~~of ~~accounting~~the ~~standards~~Company. ~~provided~~Effective ~~pursuant~~as toof ~~Section~~October 131, 2025 (athe beginning of fourth quarter of 2025), the salary of Mr. Jorden is $325,000 and the ~~Exchange~~salary ~~Act~~of Mr. ☐ Clausen is $290,000. In approving the salary increases, the Committee considered, among other factors, the improvement in the Company’s business and financial condition in 2025 compared to prior years.

Item 15.0108 ~~Entry~~Shareholder ~~into~~Director ~~a Material Definitive Agreement~~Nominations.

OnTo ~~May~~the ~~14,~~extent ~~2025~~applicable, ~~Nuo~~the ~~Therapeutics,~~information ~~Inc.~~in ~~(“Nuo”)~~Item ~~and Smith+Nephew, Inc~~8.01 ~~(“Smith+Nephew”)~~of ~~entered~~this ~~into~~Current ~~Amendment~~Report ~~No.~~on 1Form ~~(the~~8-K ~~“Amendment”)~~is toincorporated ~~their~~by ~~Distribution~~reference ~~Agreement~~into ~~dated~~this ~~March~~Item ~~31, 2025 (the “Distribution Agreement”)~~5.08.

~~The~~Item Amendment provides for an interim sales agency arrangement whereby Smith+Nephew is entitled to act as sales agent on an interim basis for the sale of products under the Nuo Aurix brand to certain Smith+Nephew customers8.01 AsOther ~~compensation, Smith+Nephew is entitled to a commission on net sales of the Nuo branded products sold to the Smith+Nephew customers~~Events.

~~The~~On ~~Amendment~~October 7, 2025, the Board of Directors of Nuo Therapeutics, Inc. (the “Company”) determined that the Company’s ~~interim~~2025 ~~sales~~Annual ~~agency~~Meeting of ~~arrangement~~Stockholders ~~terminates~~(the ~~upon~~“Annual Meeting”) will be held at the ~~earlier~~Company’s ofprincipal executive office at 8285 El Rio, Suite 190, Houston, Texas on December 3116, 2025, or ~~the~~as ~~date~~otherwise ~~notified~~set forth in ~~writing~~the byCompany’s ~~Smith+Nephew~~notice ~~upon~~and ~~not~~proxy statement for the Annual Meeting to be filed no less than ~~thirty~~40 days’ ~~notice~~prior ofto ~~such~~the ~~termination~~Annual Meeting.

~~The~~Stockholders ~~Amendment~~of ~~supplements~~the Company who wish to have a proposal, including nominations of persons for election to the ~~provisions~~Board of Directors, considered for inclusion in the ~~Distribution~~Company’s ~~Agreement~~proxy materials for the Annual Meeting must ensure that such proposal is received by, on or before the close of business on October 20, 2025, which ~~continues~~date the Company has determined to ~~provide~~be ~~that~~a ~~Nuo~~reasonable ~~will~~time ~~supply~~before it expects to ~~Smith+Nephew~~begin to print and send its ~~own~~proxy ~~private~~materials, ~~label~~and which complies with the requirements of ~~Nuo’s~~the ~~Aurix~~Amended ~~brand~~and ~~product~~Restated By-Laws of the Company (the “By-Laws”). To be eligible for inclusion in ~~accordance~~the ~~with~~proxy ~~certain~~materials ~~fees,~~for ~~transfer~~the ~~pricing~~Annual Meeting, any such proposal must also meet the requirements set forth in the rules and ~~minimum~~regulations ~~purchase~~of ~~commitments~~the ~~for~~Securities anand ~~initial~~Exchange ~~term~~Commission and in the By-Laws. Proposals and notices must be in writing and received by the Company’s Secretary, David Jorden, addressed to: Nuo Therapeutics, Inc. Board of ~~five~~Directors, ~~years~~Attn: Secretary, 8285 El Rio, Suite 190, Houston, Texas 77054.

The foregoing descriptions of the Amendment and Distribution Agreement are qualified by reference to the full text of the Amendment, a copy of which will be filed as an exhibit to Nuo’s Quarterly Report on 10-Q for the three months ended June 30, 2025, and the Distribution Agreement, a copy of which was filed as an exhibit to Nuo’s Annual Report on 10-K for the year ended December 31, 2024. Certain confidential information in the Distribution Agreement has been omitted from the version of the Distribution Agreement filed as an exhibit, and certain confidential information in the Amendment is expected to be omitted from the version of the Amendment to be filed as an exhibit, pursuant to Item 601(b)(10) of Regulation S-K because such information is not material and is the type of information that Nuo treats as private or confidential.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Nuo Therapeutics, Inc. By: /s/ David E. Jorden David E. Jorden Chief Executive and Chief Financial Officer

	Nuo Therapeutics, Inc.


	By:	/s/ David E. Jorden
		David E. Jorden
		Chief Executive and Chief Financial Officer

Date: October 10, 2025

Date: May 15, 2025

Filing Compare · Nuo Therapeutics, Inc.